Wir freuen uns dieses Jahr als Aussteller beim Pharmakongress AUTOMA+ in Zürich dabei zu sein. Als Marktführer wurden wir, zusammen mit unserer Schwesterfirma PSA Zuführtechnik GmbH, eingeladen als einziges Unternehmen aus der Zuführtechnik teilzunehmen und die Vorteile der digitalen Zuführtechnik von RNA zu präsentieren. AUTOMA+ ist ein geschlossener Netzwerkkongress, der Führungskräfte und Pioniere des Pharmasektors zusammenbringt. We are delighted to be exhibiting at the AUTOMA+ pharmaceutical congress in Zurich this year. As the market leader, we were invited together with our sister company PSA Zuführtechnik GmbH to participate as the only company from the feeding systems technology sector to present the advantages of RNA's digital feeding systems technology. AUTOMA+ is a closed-door networking congress, which gathers leaders and pioneers of the pharmaceutical sector.
Beitrag von Rhein-Nadel Automation GmbH (RNA)
Relevantere Beiträge
-
In der Zeitschrift European Pharmaceutical Review wurde ein Artikel mit dem Titel "Advancements and knowledge gaps in ICH Q2(R2)" veröffentlicht. In ihrem Beitrag befassen sich die Autoren mit den Änderungen und neuen Anforderungen der revidierten ICH Q2(R2)-Guideline und deren Auswirkungen auf die Industrie. Zu den Autoren gehören auch Mitglieder des ECA Analytical Quality Control Group Advisory Boards. https://lnkd.in/eFfNgMNM
-
-
Looking forward to our Deep Dive at the health.tech conference in Munich together with Luisa Wasilewski, Jonas Albert and Sebastian Cornelius Retter: 🔈 Beyond the Pill is Dead, Long Live DTx Plus Pill! The New Generation of DTx and Pharma-Cooperations – DiGA and Beyond 📃 This session will explore and discuss three specific use cases, far off the beaten path of what is usually mentioned when it comes to the interplay of digital health and pharmaceutical products. The use cases will feature (1) digital therapeutics of higher risk classes (IIb) and their impact on established therapies, (2) Telemonitoring with a combination DiGAs and Drugs as well as options for digital therapeutics outside of the current reimbursement pathways by acting as leverage for the prescription-volume of pharmaceutical products. 📅 Jun 5, 11:15 AM - 12:00 PM regenold GmbH I dtXca I JensonR+ Limited I DigiHealthStart.NRW I Ute Wenning
-
-
🚀 Erweitern Sie Ihre Reichweite in der Biopharma-Branche! In einer Zeit dynamischer Marktveränderungen und steigender Nachfrage nach biopharmazeutischen Produkten bietet unsere neue Themenwelt „Biopharma-Produktion“ auf bionity.com eine einzigartige Plattform für Unternehmen, um ihre Innovationen und Lösungen einem spezialisierten Publikum zu präsentieren. Seien Sie dabei und erreichen Sie über 1,2 Millionen jährliche B2B-User, die gezielt nach Produkten und Dienstleistungen in den Bereichen Biopharma, Life Sciences und Biotech suchen. 🔍 Warum sollten Sie Teil der Themenwelt Biopharma-Produktion sein? ✅ Zielgerichtete Sichtbarkeit: Präsentieren Sie Ihre Produkte und Technologien genau dort, wo Fachleute aus der biopharmazeutischen Herstellung nach den neuesten und effizientesten Lösungen suchen. ✅ Branchenführerschaft: Stärken Sie Ihr Unternehmensprofil durch die Präsentation Ihrer Expertise und Innovationen in einem Umfeld, das sich auf hochwertige und innovative biopharmazeutische Produktionsprozesse spezialisiert hat. ✅ Neukundengewinnung: Nutzen Sie die Gelegenheit, direkt von Entscheidungsträgern gefunden und kontaktiert zu werden, die aktiv nach fortschrittlichen Lösungen und Partnerschaften suchen, um ihre Herausforderungen in der Biopharma-Produktion zu meistern. Kontaktieren Sie uns noch heute, um zu erfahren, wie Sie sich mit Ihren Branchenlösungen an der Themenwelt beteiligen und Ihre Präsenz auf bionity.com maximieren können. Neugierig? Senden Sie uns eine 📨 DM oder kontaktieren Sie uns unter https://lnkd.in/ewAScTnS. Wir freuen uns auf Ihre Nachricht! #biopharma #lifescience #biotech #b2bmarketing #biopharmazie #onlinemarketing
🧬💊 Discover the world of biopharmaceutical manufacturing! In a world where the demand for biopharmaceutical products is constantly growing, the industry faces the challenge of being not only efficient but also innovative. Here at bionity.com, we have recognized this challenge and have responded with an exciting addition to our portal: the new “Biopharmaceutical Manufacturing” topic world. For years, bionity.com has been the leading industry portal, visited annually by over 1.2 million B2B users who are specifically looking for products and suppliers in the life sciences, biotech and pharmaceutical sectors. Our expertise in the laboratory and analytics sector is undisputed. But we want more! Inspired by the feedback and the growing needs of our community, our five-person content strategy team has been brainstorming intensively and analyzing the signals from our users in detail. The result? A targeted expansion of our content relating to biopharmaceutical production - an area that is crucial for the development and manufacture of life-saving biologics. 🔬 What can you expect in the new topic world? We provide you with a wide range of information and resources for biopharmaceutical production, including technologies and processes that are essential in the manufacture of biologics. Discover solutions for sterile connection and storage solutions, as well as white papers providing practical tips for biopharmaceutical media formulation or optimizing your freezing and thawing processes. The latest news and industry trends will always keep you up to date. 👩🔬 Why is this important for you? The expansion of our portal to include biopharma production shows that we are not only specialized in the laboratory aspect (research, product development, quality control), but also offer comprehensive solutions for the entire biotechnological process. This opens up new opportunities for you to find out about the latest trends and innovations and to find the right partners for your production processes. 👁 Stay tuned and discover how bionity.com can revolutionize your work in the biopharma industry! Visit us now and immerse yourself in the world of biopharmaceutical production 👉 https://lnkd.in/e_V4y8gT 🔗 Connect with us to never miss any updates and become part of a growing community of professionals shaping the future of biopharma. #biopharma #lifescience #biotech #bionity #biopharmaceuticalmanufacturing Sartorius Stedim Biotech Álvaro Pelayo Claire Randazzo Brooks Instrument
-
President at SBMF | Medical Doctor leading pharmaceutical initiatives / Board Advisory Member
New issue of IFAPP TODAY. Check the article on SBMF.
With compliments of the IFAPP - International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine - Communication Working Group, you can read here the third edition of IFAPP TODAY of 2024! Great contributions from and about: - Introducing IFAPP President-Elect Eric Klaver - In Memoriam: Dr Dimitrios Michailidis 1944-2024 - New Leadership, New Horizons: Meet the Dynamic Board of Directors at the Helm of the Brazilian Society of Pharmaceutical Medicine - Analysis of the EMA Guidance “Guideline on computerised systems and electronic data in clinical trials” - Save-the-date ICPM 2024 - Unlocking the Future: IFAPP Webinar Explores the Promise of Cell Therapy in Medicine - Building PBPK Capabilities in Africa: #PBPK2024 - Timetable IFAPP Webinars 2024 #pharmaceuticalmedicine #clintrials #clinresearch #AI #IFAPP #ICPM2024
-
Pharmacist, driving digitalization in pharma, advocate for patient-centered care solution
Wenn #Leidenschaft unsere Schritte leitet, wird sie zu einer unerschöpflichen Kraft. Leidenschaftliche Menschen wie Simon Ittig sind Inspirationsquellen für alle, unabhängig von der Grösse ihrer Organisation. Sie zeigen uns, dass Hingabe und Begeisterung zu unglaublichen Entdeckungen führen können. Schauen Sie sich dieses Interview an, um zu entdecken, wie Leidenschaft #Forschung und #Innovation transformieren kann. #LifeForward T3 Pharmaceuticals AG
Erfahren Sie im Interview mit Gründer Simon Ittig wie T3 Pharmaceuticals AG von der akademischen Forschung an der University of Basel zu einem führenden Unternehmen in der bakteriellen Krebstherapie und zu einem Teil von Boehringer Ingelheim geworden ist ➡️ https://lnkd.in/erYYMB23 #LifeForward
-
-
Don't miss "Enhancing the Ocular Surface: New Formulations and Novel Mechanisms of Action, With Drs. Lisa Nijm and Francis Mah" on MedEd Talks! In this podcast, Drs. Nijm and Mah discuss recent advances for optimizing the ocular surface, including evidence-based approaches for treating dry eye disease. This activity is supported by educational grants from Alcon Vision, LLC; Sun Pharmaceutical Industries, Inc.; and Tarsus Pharmaceuticals, Inc. Find it here: https://lnkd.in/eMGDEEQ4
-
-
Biosimilars: Bis 2032 werden insgesamt 26 “High Sales”-Präparate den Patentschutz verlieren und für mehr als ein Viertel ist derzeit noch kein Biosimilar in Entwicklung. Trotz Einsparungspotenzial im Gesundheitswesen und dem erweiteren Zugang von Patienten zu innovativen Therapien gibt es nicht für alle umsatzstarken (> 500 Mio. €) #Biologika in Europa eine Pipeline für #Biosimilars. Lesen Sie hier mehr zur Wettbewerbsituation von Biosimilars in Europa: https://bit.ly/3ICi5Qk #IQVIAInsights #Biologics #Biosimilars
Report lesen "Assessing the Biosimilar Void"
iqvia.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Nuvalent's $350M offering; FDA lifts partial hold on Zentalis drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #productmarketing #pharma
Nuvalent's $350M offering; FDA lifts partial hold on Zentalis drug
endpts.com
-
#Lyo #Gefriertrockner #ALUS #Fülllinie #Inspektion #Chromatographie #Aseptisch #Pharma #Tofflon #Biotechnologie #Fermentation #Isolatorentechnik #mAbs #GMP #Annex1 #Sterile #API #Insulin #Upstream #Downstream #Perfusion
Sie arbeiten in der Entwicklung? Neue Verfahren, neue Pharmaprodukte prägen Ihren Alltag? Dann ist dies vielleicht interessant für Sie ‼️👇👇👇 #Tofflon unterstützt! #Tofflon entwickelt! ➡️ info@tofflon.de
Discover how Tofflon can help in providing new drug delivery solutions. 🗓️ Date: October 08 -10, 2024 📍 Rho Fiera Milano,Italy 👉 Booth 18B17 🌌 Tofflon Nanomedicine Preparation System A system designed to support the development of genomic drugs. Its microfluidic technology enables controlled encapsulation and delivery of nanomedicines like lipid nanoparticles (LNPs) and polymer nanoparticles (PNPs). ✨ Highlights: 🔸 Automated blending process 🔸 User-friendly operation 🔸 Consistent uniformity and repeatability 🤹♂️ The Nanomedicine Preparation System empowers you to: 🔹 unlock more possibilities of lipid encapsulation 🔹 streamline medicine development workflow 🔹 facilitate bringing new therapies forward For more information, please come and chat with our team at CPHI Milan Tofflon booth. #NanomedicinePreparation #LipidNanoparticles #GenomicDrugs #MicrofluidicTechnology #DrugDelivery #Pharmaceuticals #LNP #Tofflonlifesciences #CPHI Milan 2024
-
Early Pharmaceutical Researcher working on Antimicrobial drug development, University of South Australia
It was incredible to see the effort of University of Adelaide and the University of South Australia to bring this forum. It was a reminder that while the road to drug approval is complex, it's also an exciting journey filled with opportunities to innovate and make a tangible impact on patients' lives. The sessions were a fascinating exploration of the bottlenecks in the drug discovery and development pipeline—ranging from early-stage target identification, optimizing preclinical models, to navigating regulatory hurdles. Yet, what stood out most was the emphasis on collaboration and innovation as solutions to these challenges. Thanks to Santhni Subramaniam and Dana Bell to bring out the best part of the event which was the Drug discovery and development pipeline chart where the forum could identify the strengths at each and every stages of drug development 😇🔎😇 Key takeaways: 🔬 Leveraging AI and machine learning for faster and more accurate target validation. 💡 The growing role of patient-centric approaches in designing formulations and clinical trials. 🌍 Recognizing the need for global cooperation to accelerate the development of life-saving drugs. Thanks to Centre for Pharmaceutical Innovation (CPI) and UoA's Adelaide Drug Discovery Incubator (ADDI) for hosting this forum. Grateful to have been part of this event and looking forward to implementing these insights in my own research journey. 🌟 #DrugDiscovery #PharmaceuticalInnovation #Collaboration #LifelongLearning
Yesterday, our Centre for Pharmaceutical Innovation (CPI) and UoA’s Adelaide Drug Discovery Incubator (ADDI) hosted the inaugural "Drug Discovery & Development Forum" at the Adelaide Convention Centre. Bringing together over 150 researchers from University of South Australia and University of Adelaide, the Forum highlighted the exceptional drug discovery and development expertise across both institutions through 20 presentations, panel discussions, poster sessions, and a pipeline mapping activity. Introduced by DAVID WAUGH (PVC Health and Medical Research, UoA), with support from MTPConnect’s Dana Bell and Santhni Subramaniam, the event marked the start of a collaborative series to foster partnerships and accelerate therapeutic innovation. A report capturing key outcomes will inform future research strategies, paving the way for success in Adelaide University. Thanks Rouven Becker, Alan Boddy, Kellie La Fontaine, Leah Welstead, Clive Prestidge for the effort in making the event a big success. Get in touch, if you want to be a part of this community.
-
Global Business Development Manager at RNA Automation Ltd
1 MonatHave a great show.